- Home
- CNOBP vs CANF Comparison
CNOBP vs CANF Comparison
Compare CNOBP & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOBP | CANF |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Israel |
| Employees | 493 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 5.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CNOBP | CANF |
|---|---|---|
| Price | $24.70 | $4.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | N/A | ★ 74.6K |
| Earning Date | N/A | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $3.36 |
| 52 Week High | N/A | $46.60 |
Technical Indicators
Market Signals| Indicator | CNOBP | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 66.46 | 64.56 |
| Support Level | $24.50 | $4.00 |
| Resistance Level | $24.73 | $4.32 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 85.36 | 31.61 |
Price Performance
Historical ComparisonAbout CNOBP ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.